We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Blocking Suppressor Signals Promotes Tumor Growth

By Biotechdaily staff writers
Posted on 11 Nov 2002
A study has found that overexpression of the gene for Ski protein, a naturally occurring human protein, interferes with the activity of the tumor suppressing transforming growth factor-beta (TGF-beta) and promotes the development of cancer cells. More...
The study was published in the November 1, 2002, issue of Cell.

TGF-beta normally binds to receptor proteins on the cell's outer surface. The signal generated by this interaction is transported across the cell membrane and activates proteins first in the cytoplasm and ultimately in the nucleus. The action of the signaling proteins activates genes necessary for the normal functioning of the cell.

By using x-ray diffraction to study crystals of purified Ski-TGF-beta complex, researchers from Princeton University (Princeton, NJ, USA; www.princeton.edu) and the Brookhaven National Laboratory (Berkley, CA, USA; www.bnl.gov) learned that in addition to previous findings that Ski had a direct effect on genes, Ski also disrupts the cytoplasmic signaling proteins. When Ski binds to the nuclear signaling proteins, the cytoplasmic signaling proteins cannot attach to their nuclear counterparts. "This binding process is probably one of the major ways in which Ski disrupts the signaling proteins and, thus, suppresses the action of TGF-beta,” explained senior author Dr. Yigong Shi, a molecular biologist at Princeton University.

"We now have a very important clue as to how Ski interferes with key proteins that prevent cells from becoming cancerous,” said Dr. Shi. "Ski is not merely recruiting proteins that repress genes; it can also disrupt signaling proteins, which makes Ski a more effective tumor-inducing protein. Understanding how to stop Ski from disrupting the normal function of cells will probably be key to developing new anticancer drugs.”



Related Links:
Princeton University
Brookhaven National Laboratory

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.